EFFECTS OF HIGH DOSES OF ALLOPURINOL ON SERUM URIC
ACID AND CARDIAC BIOMARKERS IN CHRONIC HEART FAILURE
ADRIANA ILIEŞIU1*, ALEXANDRU CÂMPEANU1, DACIANA MARTA2, GABRIELA USCOIU1, IRINA PÂRVU1, ANA CIOBANU1, MARIANA JINGA3, GABRIELA GHEORGHE1
1”Carol Davila” University of Medicine and Pharmacy, "Prof. Dr. Th. Burghele” Clinical Hospital, Department of Internal
Medicine and Cardiology, 20th Panduri Rd, Bucharest, Romania
2”Victor Babes” National Institute of Pathology and Biomedical Research, 99-101th Splaiul Independentei St, Bucharest,
Romania
3”Dr. Carol Davila” Central Military Emergency Hospital, Department of Internal Medicine, 88th Mircea Vulcanescu St.,
Bucharest, Romania
*corresponding author: adilies@yahoo.com
DownloadDownload Full Article

Abstract:
Allopurinol, by xanthine oxidase inhibition, could be a therapeutic option in patients with chronic heart failure (CHF). The
purpose of the study was to assess the effects of high dose allopurinol on serum uric acid (sUA) and cardiac biomarkers, Nterminal
pro-brain natriuretic peptide (NT-proBNP), growth differentiation factor-15 (GDF-15) and osteopontin (OPN), in
patients with CHF. In 57 patients with stable CHF, New York Heart Association (NYHA) class III and reduced systolic
function, under optimal medical therapy, ejection fraction (EF) and E/e’ ratio as markers of left ventricular function were
assessed by echocardiography. sUA, NT-proBNP, GDF-15 and OPN were measured before and after 6 months of treatment
with allopurinol 600 mg/day. Patients with elevated filling pressures (E/e’ ≥ 13) at baseline had lower EF and higher levels of
NTproBNP, GDF 15 and sUA. After 6 months, for 23 patients (40%) who improved their NYHA class, also the levels of NTproBNP
and GDF 15 decreased, along with lower sUA values. OPN was elevated at baseline and increased even further after
6 months, being unaffected by the CHF clinical course. Treatment with high doses of allopurinol was favourable, but
heterogeneous effects were registered on cardiac biomarkers in CHF patients. Since the therapeutic benefits were associated
with important sUA level decrease, sUA is a useful marker of CHF outcome and efficiency of allopurinol treatment.






Top